CTNNA3 is a tumor suppressor in hepatocellular carcinomas and is inhibited by miR-425

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern and a leading cause of cancer-related mortality.
• Understanding the molecular mechanisms driving HCC progression is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the role of the cell-cell adhesion gene CTNNA3 in hepatocellular carcinoma.
• To elucidate the regulatory relationship between CTNNA3 and microRNA-425 (miR-425) in HCC.

Main Methods:

• In vitro studies using HCC cell lines to assess the functional impact of CTNNA3 on proliferation, migration, and invasion.
• Analysis of the Akt signaling pathway, PCNA, MMP-9, and p21(Cip1/Waf1) expression.
• Luciferase reporter assays to confirm direct binding of miR-425 to the 3'UTR of CTNNA3.
• In vivo experiments using HCC cell xenografts in nude mice.

Main Results:

• CTNNA3 demonstrated tumor suppressor activity in HCC by inhibiting cell proliferation, migration, and invasion.
• CTNNA3 suppressed the Akt signaling pathway, leading to decreased PCNA and MMP-9, and increased p21(Cip1/Waf1) expression.
• miR-425 directly targets CTNNA3, inhibiting its expression and promoting HCC progression. Both CTNNA3's tumor suppressive and miR-425's oncogenic functions were confirmed in vivo.

Conclusions:

• The CTNNA3 gene functions as a tumor suppressor in hepatocellular carcinoma.
• The miR-425/CTNNA3 regulatory axis plays a critical role in HCC pathogenesis.
• Targeting the miR-425/CTNNA3 pathway presents a potential therapeutic strategy for HCC.